2013’s Top Biopharma Dealmakers
Executive Summary
Biopharma firms exchanged licenses for cancer assets more than any other therapeutic area in 2013; also in the cancer field, Amgen completed the largest acquisition, buying Onyx for $9.2 billion. J&J was the leader in alliances, penning 20 deals.
You may also be interested in...
Biopharma In 2013: A Rising Tide
Big launches, clinical success in key therapeutic areas like cancer immunotherapy, and renewed interest in biotech from a broad investor base floated the biopharma world through 2013’s average year for FDA approvals, the rocky rollout of the Affordable Care Act, and increasing concern about drug prices.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”